-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, OJ0BbXY+gOoBNLYVFiL2AJO1TsHRZh1WlyN2QvUU6D/g7ZtCd3dGAWcoYEpNtynU iNQq8r8xM1R5DJeUb7Dd8g== 0000062391-99-000012.txt : 19991224 0000062391-99-000012.hdr.sgml : 19991224 ACCESSION NUMBER: 0000062391-99-000012 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 19991223 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: OSI PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000729922 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 133159796 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: SEC FILE NUMBER: 005-37954 FILM NUMBER: 99779479 BUSINESS ADDRESS: STREET 1: 106 CHARLES LINDBERGH BLVD CITY: UNIONDALE STATE: NY ZIP: 11553 BUSINESS PHONE: 5162220023 MAIL ADDRESS: STREET 1: 106 CHARLES LINDBERGH BLVD CITY: UNIONDALE STATE: NY ZIP: 11553-3649 FORMER COMPANY: FORMER CONFORMED NAME: ONCOGENE SCIENCE INC DATE OF NAME CHANGE: 19920703 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: HOECHST MARION ROUSSEL INC CENTRAL INDEX KEY: 0000062391 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 440565557 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 10236 MARION PARK DRIVE STREET 2: P O BOX 9627 CITY: KANSAS CITY STATE: MO ZIP: 64134-0627 BUSINESS PHONE: 8169665000 MAIL ADDRESS: STREET 1: 10236 MARION PARK DRIVE STREET 2: P O BOX 9627 CITY: KANSAS CITY STATE: MO ZIP: 64134-0627 FORMER COMPANY: FORMER CONFORMED NAME: MARION MERRELL DOW INC DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: MARION LABORATORIES INC DATE OF NAME CHANGE: 19891218 SC 13G/A 1 AMENDMENT NO. 1 TO SCHEDULE 13G =========================================================================== SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 1 Under the Securities Exchange Act of 1934 OSI PHARMACEUTICALS, INC. (Formerly Oncogene Science, Inc.) ---------------------------------- (Name of Issuer) COMMON STOCK, $.01 PAR VALUE - --------------------------------------------------------------------------- (Title of Class of Securities) 682305 10 7 ----------------- (CUSIP Number) November 30, 1999 ------------------------------------------------------- (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which theis Schedule is filed: [ ] Rule 13d-1(b) [ x ] Rule 13d-1(c) [ ] Rule 13d-1(d) =========================================================================== Page 1 of 9 Exhibit Index is located at page 8 2 CUSIP No. 682305 10 7 - --------------------------------------------------------------------------- 1) Name of Reporting Person and its Aventis Pharmaceuticals Inc. I.R.S. Identification Number 44-0565557 - --------------------------------------------------------------------------- 2) Check the Appropriate Box if (a)[ ] a Member of a Group (b)[ x ] - --------------------------------------------------------------------------- 3) SEC Use Only - --------------------------------------------------------------------------- 4) Citizenship or Place of Organization Delaware - --------------------------------------------------------------------------- 5) Sole Voting Power 661,400 Number of ____________________________________________________ Shares Beneficially 6) Shared Voting Power 0 Owned by ____________________________________________________________ Each Reporting 7) Sole Dispositive Power 661,400 Person With ____________________________________________________________ 8) Shared Dispositive Power 0 - --------------------------------------------------------------------------- 9) Aggregate Amount Beneficially Owned 661,400 by Each Reporting Person - --------------------------------------------------------------------------- 10) Check Box If the Aggregate Amount [ ] in Row (9) Excludes Certain Shares - --------------------------------------------------------------------------- 11) Percent of Class Represented 3.1% by Amount in Row (9) - --------------------------------------------------------------------------- 12) Type of Reporting Person CO - --------------------------------------------------------------------------- 3 CUSIP No. 682305 10 7 13G - --------------------------------------------------------------------------- 1) Name of Reporting Person and its HMR Pharma, Inc. I.R.S. Identification Number 43-1769328 - --------------------------------------------------------------------------- 2) Check the Appropriate Box if (a)[ ] a Member of a Group (b)[ x ] - --------------------------------------------------------------------------- 3) SEC Use Only - --------------------------------------------------------------------------- 4) Citizenship or Place of Organization Delaware - --------------------------------------------------------------------------- 5) Sole Voting Power 661,400 Number of ____________________________________________________ Shares Beneficially 6) Shared Voting Power 0 Owned by ____________________________________________________________ Each Reporting 7) Sole Dispositive Power 661,400 Person With ____________________________________________________________ 8) Shared Dispositive Power 0 - --------------------------------------------------------------------------- 9) Aggregate Amount Beneficially Owned 661,400 by Each Reporting Person - --------------------------------------------------------------------------- 10) Check Box If the Aggregate Amount [ ] in Row (9) Excludes Certain Shares - --------------------------------------------------------------------------- 11) Percent of Class Represented 3.1% by Amount in Row (9) - --------------------------------------------------------------------------- 12) Type of Reporting Person CO - --------------------------------------------------------------------------- 4 CUSIP No. 682305 10 7 13G This Amendment No. 1 to the Statement on Schedule 13G with respect to the Common Stock of OSI Pharmaceuticals, Inc. (formerly Oncogene Science, Inc.) (the "Issuer"), is filed jointly by Aventis Pharmaceuticals Inc., a Delaware corporation ("Aventis"), and HMR Pharma, Inc., a Delaware corporation ("Pharma"), to reflect the change of name of Hoechst Marion Roussel, Inc., to Aventis Pharmaceuticals Inc. and to report the termination of the Schedule 13G filing obligation of Aventis and Pharma with respect to beneficial ownership of securities of the Issuer. The following items of the Statement on Schedule 13G are hereby amended to read as follows: ITEM 2(a). NAME OF PERSON FILING: - ---------- ---------------------- Aventis Pharmaceuticals Inc. HMR Pharma, Inc. ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE: - ---------- ------------------------------------------------------------ Aventis Pharmaceuticals Inc. 10236 Marion Park Drive Kansas City, Missouri 64137-1405 HMR Pharma, Inc. 10236 Marion Park Drive Kansas City, Missouri 64137-1405 ITEM 2(c). CITIZENSHIP: - ---------- ------------ Delaware As To Both Aventis Pharmaceuticals Inc. And HMR Pharma, Inc. 5 CUSIP No. 682305 10 7 13G ITEM 4. OWNERSHIP - ------- --------- (a): AMOUNT BENEFICIALLY OWNED: As Of 7/31/99 661,400 Shares Of Common Stock. A Warrant to Purchase up to 500,000 Warrant Shares at $5.50 Per Share expired on December 10, 1999. (b): PERCENT OF CLASS: 3.1% (c): NUMBER OF SHARES AS TO WHICH SUCH PERSON HAS: (i) Sole power to vote or to direct the vote: 661,400 (ii) Shared power to vote or to direct the vote: 0 (iii) Sole power to dispose or to direct the 661,400 disposition of: (iv) Shared power to dispose or to direct the 0 disposition of: ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS - ------- --------------------------------------------- If this statement is being filed to report the fact that as of the date hereof the reporting persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [ x ] 6 CUSIP No. 682305 10 7 13G SIGNATURE ---------- After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. AVENTIS PHARMACEUTICALS INC. Date: December 22, 1999 By: /s/ Rebecca R. Tilden ---------------------------- Rebecca R. Tilden Vice President and Secretary 7 CUSIP No. 682305 10 7 13G SIGNATURE ---------- After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. HMR PHARMA, INC. Date: December 22, 1999 By: /s/ Rebecca R. Tilden ---------------------------- Rebecca R. Tilden Vice President and Assistant Secretary 8 CUSIP No. 682305 10 7 13G EXHIBIT INDEX Exhibit No. Description Page No. - ----------- ------------ --------- 99.A Agreement to File Jointly dated December 9 22, 1999, by and between Aventis Pharmaceuticals Inc. and HMR Pharma, Inc. 9 CUSIP No. 682305 10 7 13G EXHIBIT 99.A AGREEMENT TO FILE JOINTLY We, the undersigned, hereby express our agreement that the attached Schedule 13G is filed on behalf of each of us. AVENTIS PHARMACEUTICALS INC. Date: December 22, 1999 By: /s/ Rebecca R. Tilden ------------------------------- Rebecca R. Tilden Vice President and Secretary HMR PHARMA, INC. Date: December 22, 1999 By: /s/ Rebecca R. Tilden -------------------------- Rebecca R. Tilden Vice President and Assistant Secretary -----END PRIVACY-ENHANCED MESSAGE-----